CellSight Technologies
CellSight Technologies is a US-based imaging company that leads 2 cancer trials in OnCo, testing the activated T-cell PET tracer [18F]F-AraG (VisAcT) in non-small-cell lung cancer.
Overview
CellSight Technologies develops molecular imaging agents that originated in Sanjiv Gambhir's laboratory at Stanford University. Its lead agent VisAcT ([18F]F-AraG) is a PET tracer that accumulates in activated T cells, intended to help select patients for immunotherapy, assess early response and detect immune-related side effects. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06107374 (phase 2, Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG) and NCT06084806 (phase 2, Test-retest Evaluation of [18F]F-AraG PET). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.